[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fAdQvqFePE6zKCAmytJp-tIABRC5i8U4wnJCVfXKIEaw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":42,"rows":49},"Seattle Institute for Biomedical and Clinical Research",[4],48,false,9,4,13297,2,21,[14,16,19,21,23,25,27,29],{"name":15,"count":9},"Stress Disorders, Post-Traumatic",{"name":17,"count":18},"Alcoholism",3,{"name":20,"count":18},"Obesity",{"name":22,"count":18},"Posttraumatic Stress Disorder",{"name":24,"count":11},"Impaired Glucose Tolerance",{"name":26,"count":11},"Irritable Bowel Syndrome",{"name":28,"count":11},"Sleep Disorders",{"name":30,"count":11},"Alzheimer's Disease",[32,37],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT04301765","Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency","2026-11-01","testosterone 1.62% gel",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04049331","Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone","2027-01-30","Testosterone Undecanoate 750 MG\u002F3 ML Intramuscular Solution [AVEED]",[43,44,45,46,47,48],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[50,76,98,125,143,169,195,221,247,265,290,316,340,364,382,406,433,461,479,547,583,612,630,648,673,699,724,751],{"intervention":36,"totalTrials":51,"cells":52},1,{"EARLY_PHASE1":53,"PHASE1":56,"PHASE2":58,"PHASE3":70,"PHASE4":72,"NA":74},{"trials":54,"activeCount":55},[],0,{"trials":57,"activeCount":55},[],{"trials":59,"activeCount":51,"soonestReadout":35},[60],{"nctId":33,"briefTitle":34,"status":61,"phases":62,"primaryCompletion":35,"completion":35,"start":63,"enrollment":64,"conditions":65,"interventions":69},"RECRUITING",[45],"2021-01-12",230,[66,67,68],"Hypogonadism, Male","Cancer","Fatigue",[36],{"trials":71,"activeCount":55},[],{"trials":73,"activeCount":55},[],{"trials":75,"activeCount":55},[],{"intervention":41,"totalTrials":51,"cells":77},{"EARLY_PHASE1":78,"PHASE1":80,"PHASE2":82,"PHASE3":92,"PHASE4":94,"NA":96},{"trials":79,"activeCount":55},[],{"trials":81,"activeCount":55},[],{"trials":83,"activeCount":51,"soonestReadout":40},[84],{"nctId":38,"briefTitle":39,"status":85,"phases":86,"primaryCompletion":40,"completion":40,"start":87,"enrollment":88,"conditions":89,"interventions":91},"ACTIVE_NOT_RECRUITING",[45],"2021-03-22",240,[66,90],"Fatigue Syndrome, Chronic",[41],{"trials":93,"activeCount":55},[],{"trials":95,"activeCount":55},[],{"trials":97,"activeCount":55},[],{"intervention":99,"totalTrials":51,"cells":100},"simvastatin",{"EARLY_PHASE1":101,"PHASE1":103,"PHASE2":105,"PHASE3":107,"PHASE4":109,"NA":123},{"trials":102,"activeCount":55},[],{"trials":104,"activeCount":55},[],{"trials":106,"activeCount":55},[],{"trials":108,"activeCount":55},[],{"trials":110,"activeCount":55},[111],{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":121},"NCT00303277","Do HMG CoA Reductase Inhibitors Affect Abeta Levels?","COMPLETED",[47],"2005-04","2002-08",35,[30,120],"Aging",[99,122],"pravastatin",{"trials":124,"activeCount":55},[],{"intervention":122,"totalTrials":51,"cells":126},{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":133,"PHASE4":135,"NA":141},{"trials":128,"activeCount":55},[],{"trials":130,"activeCount":55},[],{"trials":132,"activeCount":55},[],{"trials":134,"activeCount":55},[],{"trials":136,"activeCount":55},[137],{"nctId":112,"briefTitle":113,"status":114,"phases":138,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":139,"interventions":140},[47],[30,120],[99,122],{"trials":142,"activeCount":55},[],{"intervention":144,"totalTrials":51,"cells":145},"galantamine",{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":154,"NA":167},{"trials":147,"activeCount":55},[],{"trials":149,"activeCount":55},[],{"trials":151,"activeCount":55},[],{"trials":153,"activeCount":55},[],{"trials":155,"activeCount":55},[156],{"nctId":157,"briefTitle":158,"status":159,"phases":160,"primaryCompletion":161,"completion":161,"start":162,"enrollment":12,"conditions":163,"interventions":166},"NCT00232349","Efficacy of Galantamine to Treat Schizophrenia","TERMINATED",[47],"2007-06","2005-02",[164,165],"Schizophrenia","Psychotic Disorder",[144],{"trials":168,"activeCount":55},[],{"intervention":170,"totalTrials":51,"cells":171},"quetiapine",{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":193},{"trials":173,"activeCount":55},[],{"trials":175,"activeCount":55},[],{"trials":177,"activeCount":55},[],{"trials":179,"activeCount":55},[],{"trials":181,"activeCount":55},[182],{"nctId":183,"briefTitle":184,"status":114,"phases":185,"primaryCompletion":186,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":192},"NCT00232336","Quetiapine for Cocaine Use and Cravings",[47],"2006-01","2003-10",42,[190,191],"Cocaine-Related Disorders","Substance-Related Disorders",[170],{"trials":194,"activeCount":55},[],{"intervention":196,"totalTrials":51,"cells":197},"H. pylori treatment",{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":217,"NA":219},{"trials":199,"activeCount":55},[],{"trials":201,"activeCount":55},[],{"trials":203,"activeCount":55},[],{"trials":205,"activeCount":55},[206],{"nctId":207,"briefTitle":208,"status":114,"phases":209,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":216},"NCT00202488","The Effect of H. Pylori Infection on Iron Metabolism",[45,46],"2007-09","2002-11",39,[214,215],"Iron Deficiency Anemia","Helicobacter Pylori Infection",[196],{"trials":218,"activeCount":55},[],{"trials":220,"activeCount":55},[],{"intervention":222,"totalTrials":51,"cells":223},"Naproxen Sodium",{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":243,"NA":245},{"trials":225,"activeCount":55},[],{"trials":227,"activeCount":55},[],{"trials":229,"activeCount":55},[],{"trials":231,"activeCount":55},[232],{"nctId":233,"briefTitle":234,"status":114,"phases":235,"primaryCompletion":236,"start":237,"enrollment":238,"conditions":239,"interventions":241},"NCT00007189","Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)",[46],"2007-05","2001-01",2625,[240],"Alzheimer Disease",[222,242],"Celecoxib",{"trials":244,"activeCount":55},[],{"trials":246,"activeCount":55},[],{"intervention":242,"totalTrials":51,"cells":248},{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":255,"PHASE4":261,"NA":263},{"trials":250,"activeCount":55},[],{"trials":252,"activeCount":55},[],{"trials":254,"activeCount":55},[],{"trials":256,"activeCount":55},[257],{"nctId":233,"briefTitle":234,"status":114,"phases":258,"primaryCompletion":236,"start":237,"enrollment":238,"conditions":259,"interventions":260},[46],[240],[222,242],{"trials":262,"activeCount":55},[],{"trials":264,"activeCount":55},[],{"intervention":266,"totalTrials":51,"cells":267},"Colesevelam",{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":274,"PHASE4":286,"NA":288},{"trials":269,"activeCount":55},[],{"trials":271,"activeCount":55},[],{"trials":273,"activeCount":55},[],{"trials":275,"activeCount":55},[276],{"nctId":277,"briefTitle":278,"status":114,"phases":279,"primaryCompletion":280,"completion":280,"start":281,"enrollment":12,"conditions":282,"interventions":285},"NCT00990184","Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)",[46],"2010-10","2009-09",[283,284],"Impaired Fasting Glucose","Prediabetes",[266],{"trials":287,"activeCount":55},[],{"trials":289,"activeCount":55},[],{"intervention":291,"totalTrials":51,"cells":292},"divalproex sodium extended release",{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":312,"NA":314},{"trials":294,"activeCount":55},[],{"trials":296,"activeCount":55},[],{"trials":298,"activeCount":55},[],{"trials":300,"activeCount":55},[301],{"nctId":302,"briefTitle":303,"status":114,"phases":304,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":311},"NCT00202514","Placebo Controlled Trial of Depakote ER in Alcohol Dependent Patients With Mood and\u002For Anxiety Symptoms",[45,46],"2006-07","2004-09",40,[17,309,310],"Alcohol Related Disorders","Mood Disorders",[291],{"trials":313,"activeCount":55},[],{"trials":315,"activeCount":55},[],{"intervention":317,"totalTrials":51,"cells":318},"long-acting injectable risperidone",{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":334,"PHASE4":336,"NA":338},{"trials":320,"activeCount":55},[],{"trials":322,"activeCount":55},[],{"trials":324,"activeCount":55},[325],{"nctId":326,"briefTitle":327,"status":114,"phases":328,"primaryCompletion":329,"completion":329,"start":186,"enrollment":330,"conditions":331,"interventions":333},"NCT00284206","A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence",[45],"2007-08",20,[332],"Methamphetamine Dependence",[317],{"trials":335,"activeCount":55},[],{"trials":337,"activeCount":55},[],{"trials":339,"activeCount":55},[],{"intervention":341,"totalTrials":51,"cells":342},"Climara",{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":358,"PHASE4":360,"NA":362},{"trials":344,"activeCount":55},[],{"trials":346,"activeCount":55},[],{"trials":348,"activeCount":55},[349],{"nctId":350,"briefTitle":351,"status":114,"phases":352,"completion":353,"start":354,"enrollment":307,"conditions":355,"interventions":356},"NCT00220454","Effect of Estrogen & Stress for Postmenopausal Women",[45],"2005-03","2002-12",[120],[341,357],"Hydrocortone",{"trials":359,"activeCount":55},[],{"trials":361,"activeCount":55},[],{"trials":363,"activeCount":55},[],{"intervention":357,"totalTrials":51,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":376,"PHASE4":378,"NA":380},{"trials":367,"activeCount":55},[],{"trials":369,"activeCount":55},[],{"trials":371,"activeCount":55},[372],{"nctId":350,"briefTitle":351,"status":114,"phases":373,"completion":353,"start":354,"enrollment":307,"conditions":374,"interventions":375},[45],[120],[341,357],{"trials":377,"activeCount":55},[],{"trials":379,"activeCount":55},[],{"trials":381,"activeCount":55},[],{"intervention":383,"totalTrials":51,"cells":384},"Prazosin medication",{"EARLY_PHASE1":385,"PHASE1":387,"PHASE2":389,"PHASE3":400,"PHASE4":402,"NA":404},{"trials":386,"activeCount":55},[],{"trials":388,"activeCount":55},[],{"trials":390,"activeCount":55},[391],{"nctId":392,"briefTitle":393,"status":114,"phases":394,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":399},"NCT00762710","Study of the Medication Prazosin for Alcohol Dependence",[45],"2014-06","2008-01",92,[17],[383],{"trials":401,"activeCount":55},[],{"trials":403,"activeCount":55},[],{"trials":405,"activeCount":55},[],{"intervention":407,"totalTrials":51,"cells":408},"Naltrexone",{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":427,"PHASE4":429,"NA":431},{"trials":410,"activeCount":55},[],{"trials":412,"activeCount":55},[],{"trials":414,"activeCount":55},[415],{"nctId":416,"briefTitle":417,"status":114,"phases":418,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":425},"NCT02322047","Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders",[45],"2018-10-10","2015-03-03",31,[423,424],"Alcohol Use Disorder","Posttraumatic Stress Disorder (PTSD)",[426,407],"Prazosin",{"trials":428,"activeCount":55},[],{"trials":430,"activeCount":55},[],{"trials":432,"activeCount":55},[],{"intervention":434,"totalTrials":51,"cells":435},"Carboplatin",{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":455,"PHASE4":457,"NA":459},{"trials":437,"activeCount":55},[],{"trials":439,"activeCount":55},[],{"trials":441,"activeCount":55},[442],{"nctId":443,"briefTitle":444,"status":159,"phases":445,"primaryCompletion":446,"completion":446,"start":447,"enrollment":11,"conditions":448,"interventions":453},"NCT02985021","Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies",[45],"2021-04","2016-11",[449,450,451,452],"Hormone-Resistant Prostate Cancer","Metastatic Prostate Carcinoma","Recurrent Prostate Carcinoma","Stage IV Prostate Cancer",[434,454],"Docetaxel",{"trials":456,"activeCount":55},[],{"trials":458,"activeCount":55},[],{"trials":460,"activeCount":55},[],{"intervention":454,"totalTrials":51,"cells":462},{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":473,"PHASE4":475,"NA":477},{"trials":464,"activeCount":55},[],{"trials":466,"activeCount":55},[],{"trials":468,"activeCount":55},[469],{"nctId":443,"briefTitle":444,"status":159,"phases":470,"primaryCompletion":446,"completion":446,"start":447,"enrollment":11,"conditions":471,"interventions":472},[45],[449,450,451,452],[434,454],{"trials":474,"activeCount":55},[],{"trials":476,"activeCount":55},[],{"trials":478,"activeCount":55},[],{"intervention":426,"totalTrials":480,"cells":481},6,{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":501,"PHASE4":503,"NA":516},{"trials":483,"activeCount":55},[],{"trials":485,"activeCount":55},[],{"trials":487,"activeCount":55},[488,497],{"nctId":489,"briefTitle":490,"status":114,"phases":491,"primaryCompletion":492,"completion":492,"start":281,"enrollment":493,"conditions":494,"interventions":496},"NCT01518972","Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder",[45],"2012-06",30,[495,22],"Alcohol Abuse",[426],{"nctId":416,"briefTitle":417,"status":114,"phases":498,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":499,"interventions":500},[45],[423,424],[426,407],{"trials":502,"activeCount":55},[],{"trials":504,"activeCount":55},[505],{"nctId":506,"briefTitle":507,"status":114,"phases":508,"primaryCompletion":509,"completion":510,"start":511,"enrollment":512,"conditions":513,"interventions":515},"NCT02965027","Prazosin for Post-Concussive Headaches",[47],"2023-05-09","2023-06-07","2016-11-29",89,[514],"Post-Traumatic Headache",[426],{"trials":517,"activeCount":55},[518,529,537],{"nctId":519,"briefTitle":520,"status":159,"phases":521,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":526},"NCT00202449","Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance",[48],"2008-02","2004-07",59,[15,28],[527,528],"prazosin","paroxetine",{"nctId":530,"briefTitle":531,"status":114,"phases":532,"primaryCompletion":533,"completion":533,"start":534,"enrollment":330,"conditions":535,"interventions":536},"NCT01126099","Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease",[48],"2014-03","2010-03",[30],[426],{"nctId":538,"briefTitle":539,"status":159,"phases":540,"primaryCompletion":541,"completion":542,"start":187,"enrollment":330,"conditions":543,"interventions":546},"NCT00183430","Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder",[48],"2009-05","2010-12",[544,545],"Post-Traumatic Stress Disorder","Sleep Initiation and Maintenance Disorders",[426],{"intervention":548,"totalTrials":11,"cells":549},"prazosin hydrochloride",{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":558,"NA":560},{"trials":551,"activeCount":55},[],{"trials":553,"activeCount":55},[],{"trials":555,"activeCount":55},[],{"trials":557,"activeCount":55},[],{"trials":559,"activeCount":55},[],{"trials":561,"activeCount":55},[562,571],{"nctId":563,"briefTitle":564,"status":114,"phases":565,"primaryCompletion":566,"completion":566,"start":281,"enrollment":567,"conditions":568,"interventions":570},"NCT00990106","Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)",[48],"2013-03",67,[15,569,28],"Combat Disorders",[548],{"nctId":572,"briefTitle":573,"status":114,"phases":574,"primaryCompletion":575,"completion":576,"start":577,"enrollment":578,"conditions":579,"interventions":582},"NCT02226367","Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD",[48],"2018-09-20","2018-10-20","2015-01",158,[580,581,569],"Alcohol Use Disorders","Stress Disorders, Posttraumatic",[548],{"intervention":584,"totalTrials":51,"cells":585},"quetiapine fumarate",{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":592,"PHASE4":594,"NA":596},{"trials":587,"activeCount":55},[],{"trials":589,"activeCount":55},[],{"trials":591,"activeCount":55},[],{"trials":593,"activeCount":55},[],{"trials":595,"activeCount":55},[],{"trials":597,"activeCount":55},[598],{"nctId":599,"briefTitle":600,"status":114,"phases":601,"primaryCompletion":602,"completion":602,"start":522,"enrollment":603,"conditions":604,"interventions":610},"NCT00631748","Quetiapine for the Reduction of Cocaine Use",[48],"2010-07",60,[605,606,607,608,609],"Cocaine Dependence","Cocaine Abuse","Cocaine Addiction","Drug Abuse","Substance Abuse",[584,611],"Matched Placebo",{"intervention":611,"totalTrials":51,"cells":613},{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":620,"PHASE4":622,"NA":624},{"trials":615,"activeCount":55},[],{"trials":617,"activeCount":55},[],{"trials":619,"activeCount":55},[],{"trials":621,"activeCount":55},[],{"trials":623,"activeCount":55},[],{"trials":625,"activeCount":55},[626],{"nctId":599,"briefTitle":600,"status":114,"phases":627,"primaryCompletion":602,"completion":602,"start":522,"enrollment":603,"conditions":628,"interventions":629},[48],[605,606,607,608,609],[584,611],{"intervention":528,"totalTrials":51,"cells":631},{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":638,"PHASE4":640,"NA":642},{"trials":633,"activeCount":55},[],{"trials":635,"activeCount":55},[],{"trials":637,"activeCount":55},[],{"trials":639,"activeCount":55},[],{"trials":641,"activeCount":55},[],{"trials":643,"activeCount":55},[644],{"nctId":519,"briefTitle":520,"status":159,"phases":645,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":646,"interventions":647},[48],[15,28],[527,528],{"intervention":649,"totalTrials":51,"cells":650},"GnRH agonist",{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":657,"PHASE4":659,"NA":661},{"trials":652,"activeCount":55},[],{"trials":654,"activeCount":55},[],{"trials":656,"activeCount":55},[],{"trials":658,"activeCount":55},[],{"trials":660,"activeCount":55},[],{"trials":662,"activeCount":55},[663],{"nctId":664,"briefTitle":665,"status":114,"phases":666,"primaryCompletion":667,"completion":667,"start":668,"enrollment":603,"conditions":669,"interventions":672},"NCT03867357","Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia",[],"2023-09-01","2018-12-07",[670,671],"Metastatic Prostate Cancer","Androgen Deprivation Therapy",[649],{"intervention":674,"totalTrials":51,"cells":675},"olanzapine and melatonin",{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":682,"PHASE4":684,"NA":686},{"trials":677,"activeCount":55},[],{"trials":679,"activeCount":55},[],{"trials":681,"activeCount":55},[],{"trials":683,"activeCount":55},[],{"trials":685,"activeCount":55},[],{"trials":687,"activeCount":55},[688],{"nctId":689,"briefTitle":690,"status":114,"phases":691,"primaryCompletion":542,"completion":692,"start":693,"enrollment":307,"conditions":694,"interventions":698},"NCT00512070","Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine",[48],"2024-12","2007-07",[164,695,696,20,697],"Schizoaffective Disorder","Bipolar Disorder","Metabolic Syndrome",[674],{"intervention":700,"totalTrials":51,"cells":701},"high glycemic index diet plus N-acetylcysteine",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":708,"PHASE4":710,"NA":712},{"trials":703,"activeCount":55},[],{"trials":705,"activeCount":55},[],{"trials":707,"activeCount":55},[],{"trials":709,"activeCount":55},[],{"trials":711,"activeCount":55},[],{"trials":713,"activeCount":55},[714],{"nctId":715,"briefTitle":716,"status":114,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":721,"interventions":723},"NCT01386645","Effect of Dietary Glycemic Index on Beta-cell Function",[48],"2019-08-01","2011-07",56,[24,722,284,283],"Oxidative Stress",[700],{"intervention":725,"totalTrials":51,"cells":726},"Testosterone gel",{"EARLY_PHASE1":727,"PHASE1":729,"PHASE2":731,"PHASE3":733,"PHASE4":735,"NA":737},{"trials":728,"activeCount":55},[],{"trials":730,"activeCount":55},[],{"trials":732,"activeCount":55},[],{"trials":734,"activeCount":55},[],{"trials":736,"activeCount":55},[],{"trials":738,"activeCount":55},[739],{"nctId":740,"briefTitle":741,"status":114,"phases":742,"primaryCompletion":743,"completion":744,"start":211,"enrollment":745,"conditions":746,"interventions":750},"NCT00202462","The Effect of Testosterone on Mood and Quality of Life",[48],"2005-12","2006-11",33,[747,748,749],"Gonadal Disorders","Depressive Disorder","Hypogonadism",[725],{"intervention":752,"totalTrials":51,"cells":753},"Genecept Assay and G-DIG decision tool",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":755,"activeCount":55},[],{"trials":757,"activeCount":55},[],{"trials":759,"activeCount":55},[],{"trials":761,"activeCount":55},[],{"trials":763,"activeCount":55},[],{"trials":765,"activeCount":55},[766],{"nctId":767,"briefTitle":768,"status":114,"phases":769,"primaryCompletion":770,"completion":771,"start":772,"enrollment":773,"conditions":774,"interventions":776},"NCT03468309","Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population",[],"2019-04-01","2024-04-17","2018-01-01",53,[775],"Pharmacogenetic Testing",[752]]